Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Halozyme Therapeutics
ClinicalTrials.gov Identifier:
NCT01453153
First received: October 13, 2011
Last updated: October 12, 2015
Last verified: September 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2015
  Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)